Borrow Against a Stock Portfolio? McClendon's Margin Call
Borrowing against a stock portfolio is reasonable only when the owner, not the lender, decides when shares get sold. The loan raises cash without triggering a sale, and in exchange it hands someone else the right to force one if the shares fall far enough. The interest rate is not the decision. The clock is.
In the autumn of 2008, Aubrey McClendon was co-founder and chief executive of Chesapeake Energy1 and its largest individual shareholder.1 Most of that stake was pledged as collateral for personal loans, and he had borrowed to buy still more shares — a habit he described as a show of confidence in the company's strategy. Chesapeake traded above $81.46 that summer. By early October, with natural gas prices collapsing and credit markets frozen, it had fallen into the teens.1 Over roughly three trading days he was forced to sell substantially all of his common stock to meet calls on those loans.2 He said afterward that the sales did not reflect his view of the company.2 The agreements had no clause for his view. (Chesapeake appears here as a documented illustration of lending mechanics, not as a comment on any company as an investment.)
Owners who have just turned a business into a block of stock hear a tidier version of the same arrangement: borrow against the portfolio rather than sell it, keep the upside, defer the tax. Sometimes that is sensible. Most people default to weighing the interest rate against the tax bill, but the rate is only the price of the loan — the cure clauses are the risk of it. Thirty questions can be asked about forms and wires. Three decide whether the owner still controls the holding period, and they matter most in the stretches when prices fall broadly and borrowing costs rise at the same time.
Who decides the day the shares get sold — the owner or the lender?
The governing principle is that the trigger is mechanical and the window is short. A secured loan does not cancel a sale; it postpones one on terms the lender can enforce.
Two products travel under one phrase. A margin loan is credit from a broker, often used to buy more securities: federal rules generally let the firm lend up to half the purchase price at the outset,3 and after that the account's equity — what the securities are worth minus what is owed — must generally stay above a quarter of market value under FINRA rules, not federal rules,4 with firms free to impose stricter house rules. A securities-backed line of credit, the version a private bank is more likely to offer a family that has just exited, usually cannot be used to buy securities but behaves the same way. The lender sets a loan-to-value ceiling (the loan divided by the current market value of the pledged assets) and issues a call when a decline breaches it, typically allowing a few days to post cash or other collateral. Many of these lines are also demand loans: the balance can be called for the lender's own reasons, with no price drop at all. And in the ordinary form, a sale that fails to cover the balance does not end the debt.
McClendon's shares went in the week the whole market was falling hardest, because that is precisely when a price-based trigger fires. Unleveraged holders of the same stock made no decision at all that week.
What changes if the honest answer is "the lender": the draw has to be small enough that an ordinary severe decline cannot reach the trigger. A draw at half the permitted ceiling leaves room; a draw at the ceiling leaves none. And owners who cannot get the terms in plain writing — what triggers a call, how many days a cure is allowed, whether repayment can be demanded with no price decline, who picks the shares sold — are better served selling a modest slice on their own timetable, paying the tax, and borrowing nothing.
Is the pledged stock the same bet the household already lives inside?
The governing principle is that leverage on a concentrated holding does not soften the concentration. It shortens the time until the concentration hurts.
McClendon did not pledge a quiet mix of other people's businesses. He pledged Chesapeake and used the borrowed money to buy more Chesapeake. His wealth, his collateral and his purchases were one position in natural gas, so when gas fell they all fell together, and there was no uncorrelated asset to pledge or sell instead. His own selling then became part of the decline. The loop is mechanical: a lower price means less collateral, which means more shares sold, which means a lower price.
Founders who have just exited sit in a milder version of that shape — a large block of the buyer's stock they would prefer not to sell. Concentration after an exit is already the household's main exposure before any borrowing is layered on top. And a lender marks collateral to the market that exists on the morning of the call, never to the figure the owner privately believes the holding is worth — the gap between those two numbers is where the trouble usually starts.
What changes if the answer is yes, they move together: the honest options narrow to selling a portion on a timetable the owner sets while markets are orderly, or pledging a diversified sleeve and leaving the concentrated block outside the loan entirely. Borrowing for a genuinely separate purpose — a house, a tax payment, a bridge to buying an operating business that closes on its own schedule — can be sound against diversified collateral. Borrowing to buy more of what secures the loan is the structure that produced October 2008.
What answers the call, if not the shares themselves?
When a call arrives there are only three cures: add cash, add other collateral the lender will still accept, or sell. The governing principle is that the cure has to exist before the call, in an account that is not pledged and not exposed to the same market.
The October record is blunt about what was missing. The sales were involuntary because the shares were the only check available to write. A household that borrows against a portfolio to fund a house, a tax bill or another venture has the same structure in a quieter register: if the borrowed cash is already spent on something that cannot be sold in three days, the only remaining cure is the portfolio itself. Two further details sharpen it. These loans usually float with a short-term benchmark, so the cost of carrying the debt can climb in the same stretch that collateral values fall — both moving against the borrower at once. And a forced sale can realize the very capital gain the loan was meant to defer, at a price nobody chose; tax treatment depends on the facts, but the structural point does not.
"The shares will come back" is not a cure, and neither is borrowing more against assets the lender is busy marking down. Owners who find it inconvenient to hold that much uninvested cash outside the pledge have learned something useful: the loan was never as cheap as its rate suggested. That reserve is the real price.
What changes if nothing is set aside: the owner is, in effect, planning to sell at the bottom, whether or not anyone has said so out loud. The alternatives are to build the reserve before drawing, or not to draw.
What the three answers settle
Taken together, the three questions describe one idea: a loan against stock converts a price into a deadline, and only owners who control the deadline should accept the conversion. Cure terms in plain writing with a draw well below the ceiling; proceeds that do not move with the collateral; cash outside the pledge that can answer a call without a sale. With all three, borrowing against a portfolio can be a reasonable way to avoid an unwanted sale. Fail any one, and the modest rate is a distraction — the family's largest timing decision now belongs to a counterparty whose only interest is being repaid.
The aftermath is telling. Pledged executive stock became a live governance question after 2008, and many boards adopted policies addressing how insiders could use company shares as loan collateral. The people closest to episodes like this one concluded that the structure, not the conviction, was the thing that had to change. McClendon still believed in the company on the day the shares left him. Belief was simply not one of the remedies the loan allowed.
Sources
Figures marked with a superscript were checked against these sources on November 6, 2026.
- McClendon forced to sell off his Chesapeake shares journalrecord.com — In the autumn of 2008, Aubrey McClendon was co-founder and chief executive of Chesapeake Energy.
- Chesapeake's McClendon Forced to Sell 'Substantially All' Shares naturalgasintel.com — Over roughly three trading days in early October 2008, Aubrey McClendon was forced to sell substantially all of his common stock in Chesapeake Energy to meet margin calls.
- 12 CFR § 220.12 - Supplement: margin requirements. law.cornell.edu — Federal rules generally allow a broker to lend up to half the purchase price of securities at the outset of a margin loan.
- Margin Accounts | FINRA.org finra.org — FINRA rules, not federal rules